BioLineRx to Present at 2013 Stifel Nicolaus Healthcare Conference In Boston

News provided by

Aug 27, 2013, 07:00 ET

JERUSALEM, Aug. 27, 2013 /PRNewswire/ -- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2013 Stifel Nicolaus Healthcare Conference at the Four Seasons Hotel in Boston.

(Logo: http://photos.prnewswire.com/prnh/20130730/630769)

The BioLineRx presentation is scheduled to start at 10:55 a.m. EDT on Wednesday, September 11, 2013. A live audio webcast of the presentation will be available online at the investor page of the Company's website. An archive of the event will also be available for 30 days following the conference, for those unable to listen live.

In addition, any investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact their Stifel Nicolaus representative.

About BioLineRx
BioLineRx is a publicly-traded biopharmaceutical development company dedicated to building a portfolio of products for unmet medical needs, as well as those with advantages over currently available therapies. The Company in-licenses novel compounds primarily from academic institutions and biotech companies based in Israel, develops them through pre-clinical and/or clinical stages, and then partners with pharmaceutical companies for advanced clinical development and/or commercialization.

BioLineRx's current portfolio consists of a variety of clinical and pre-clinical projects, including: BL-1040 for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc. and is in the midst of a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions, which is expected to commence a pivotal CE-mark registration trial in late 2013; BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers, which is in the midst of a Phase 2 study; and BL-7010 for celiac disease, which is expected to commence a Phase 1/2 study in late 2013.

For more information on BioLineRx, please visit www.biolinerx.com or download the investor relations mobile device app, which allows users access to the Company's SEC documents, press releases, and events. BioLineRx's IR app is available on the iTunes App Store as well as the Google Play Store.

Contact:
KCSA Strategic Communications
Garth Russell / Todd Fromer
+1 212-896-1250 / +1 212-896-1250
[email protected] / [email protected]

Tsipi Haitovsky
Public Relations
+972-3-6240871
[email protected]

SOURCE BioLineRx